Left ventricular outflow tract (LVOT) obstruction is an integral component of hypertrophic cardiomyopathy (HCM). Both chemical myomectomy and alcohol septal ablation (ASA) have been shown effective in the reduction of residual gradients and symptoms in several studies and clinical registries, and are normally reserved for patients who continue experiencing symptoms despite medical treatment. Even though…
Hypertrophic Cardiomyopathy: Analyzing a Historical Series
75% of patients with hypertrophic Cardiomyopathy present symptoms. An important group responds very well to pharmacological treatment with betablockers and calcium antagonists, and those who do not respond, or do not tolerate these drugs, receive, at present, surgery as elective treatment. There is also alcohol septal ablation as an alternative strategy, which different studies have…
ESC 2020 | New Drug Improves Functional Capacity in Hypertrophic Cardiomyopathy
In patients with hypertrophic cardiomyopathy, myosin inhibitor mavacamten plus optimal medical therapy improved hemodynamics, functional capacity, and symptoms. Mavacamten is the first myosin inhibitor drug of its class. Presented virtually at the European Society of Cardiology 2020 Congress (ESC 2020) and published simultaneously in The Lancet, the EXPLORER-HCM study showed that 37% of patients who received…